Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction, infarct stroke, degenerative disk disease and Parkinson’s Disease. Venturis Therapeutics, Inc. is focused on targeted delivery of next generation molecules which will improve the quality of life for those suffering from vascular dysfunction.
In The News
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate stimulates the growth of new blood vessels when administered to ischemic organs and tissues. These anatomical targets are shown in our pipeline section.
Peter Jennings - ABC World News report on Venturis' Heart Trial
An estimated 92,100,000 American adults (more than 1 in 3) have one or more types of cardiovascular disease (CVD). 2,300 Americans die of CVD each day, an average of one death every 38 seconds.
American Heart Association, "Heart Disease and Stroke Statistics-2018 Update"
